Background: Even though hyperuricemia has been shown to have roles in the formation of atherosclerosis and increasing incidence of coronary heart disease, its role in predicting prognosis in acute myocardial infarction (AMI) patients has not been widely studied.
Objective: This study aimed to investigate the role of hyperuricemia as a predictor of in-hospital major adverse cardiac events (MACE) and to determine the MACE-free survival difference between hyperuricemia and normouricemia patients with AMI who were hospitalized at Sanglah General Hospital.
Methods: Prospective cohort study with consecutive sampling was conducted in AMI patients who were treated at Sanglah General Hospital from November 2016 until February 2017. Uric acid level was measured at the first admission and MACE during hospitalization was observed.
Results: Eighty-seven patients were involved in this study. We found adjusted HR 1.875 (p=0.041; 95% CI 1.026-3.428) for the development of in-hospital MACE. There was a significant difference (log-rank test p=0.03) in MACE-free survival between hyperuricemia (mean survival 17.25 hours) and normouricemia (mean survival 43.389 hours) groups.
Conclusion: Hyperuricemia is an independent predictor of in-hospital MACE in AMI patients hospitalized at Sanglah General Hospital. Event-free survival of hyperuricemic patients is worse compared to normouricemia patients during hospitalization.